Back to search

Spain· ES:75112

KARBICOMBI 32 mg/25 mg COMPRIMIDOS EFG

A medicinal product containing candesartán + hidroclorotiazida, registered in Spain by Krka D.D. Novo Mesto.

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedKARBICOMBI 32 mg/25 mg COMPRIMIDOS EFGATC—REGISTER NO.ES:75112PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

AEMPS CIMA (Spain)
Active substance
candesartán + hidroclorotiazida
Manufacturer
Krka D.D. Novo Mesto
Country
Spain (ES)
ATC code
—
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cima_codigo
    686274
    28
    EUR 20.92

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Candesartán + hidroclorotiazida in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All candesartán + hidroclorotiazida products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9e53c5a0-c579-4b1b-aa95-478cf8485c24
GET /v1/drugs/9e53c5a0-c579-4b1b-aa95-478cf8485c24?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Medicamento Sujeto A Prescripción Médica",
  "estado": "{\"aut\":1335304800000}",
  "nregistro": "75112",
  "substance": "candesartán + hidroclorotiazida"
}

See everything about candesartán + hidroclorotiazida.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.